Amryt Signs Four New Lojuxta Deals in the Middle East
UK-based Amryt, a biopharmaceutical company focused on rare and orphan diseases, has announced the signing of four further distribution agreements for its Homozygous Familial Hypercholesterolaemia (HoFH) treatment, Lojuxta, across the Middle East. The agreements have been signed with Al Hafez Trading Establishment (Kuwait), Ebn Sina Medical (Qatar), Muscat Pharmacy and Stores (Oman), and Goro Healthcare (UAE/Bahrain). Amryt has signed nine distribution agreements for Lojuxta since November 2017. On the latest deals, Joe Wiley, the company's CEO, commented: “The Middle East has a higher HoFH patient population per capita than Europe and we look forward to working closely with our new distribution partners to improve patient outcomes.” An interview with Amryt's Dr. Joe Wiley will feature in the upcoming June issue of Pharmaceutical Executive.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
